These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22739569)

  • 1. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
    Trautmann K; Jakob C; von Grünhagen U; Schleyer E; Brümmendorf TH; Siegert G; Ehninger G; Platzbecker U
    Thromb Haemost; 2012 Aug; 108(2):397-8. PubMed ID: 22739569
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia.
    Modi Y; Shaaban H; Gauchan D; Maroules M
    J Oncol Pharm Pract; 2015 Feb; 21(1):74-5. PubMed ID: 25063763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag.
    Scheinberg P; Singulane CC; Barbosa LS; Scheinberg M
    Clin Rheumatol; 2014 Sep; 33(9):1347-9. PubMed ID: 24740463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
    Gauchan D; Shaaban H; Gedeon D; Maroules M
    Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecule of the month. Eltrombopag.
    Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding complex disease-related mechanisms: Rational therapies for Diamond-Blackfan anaemia.
    Lipton JM
    Br J Haematol; 2024 May; 204(5):1598-1599. PubMed ID: 38485153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory/relapsed Diamond-Blackfan anaemia with eltrombopag.
    Duncan BB; Lotter JL; Superata J; Barranta ME; Machado T; Darden I; Venugopal S; Wu CO; Abkowitz JL; Dunbar CE; Young DJ
    Br J Haematol; 2024 May; 204(5):2077-2085. PubMed ID: 38462764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag in thrombocytopenia.
    Lawson A
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18322290
    [No Abstract]   [Full Text] [Related]  

  • 9. Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.
    Uwagawa T; Misawa T; Furukawa K; Ito R; Futagawa Y; Yahagi Y; Aiba K; Yanaga K
    Acta Haematol; 2013; 129(1):45-7. PubMed ID: 23128016
    [No Abstract]   [Full Text] [Related]  

  • 10. [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
    Guglieri-López B; Ventura-Cerdá JM; Carmena-Carmena J; Climente-Mónica M
    Farm Hosp; 2013; 37(5):419-21. PubMed ID: 24128106
    [No Abstract]   [Full Text] [Related]  

  • 11. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia.
    Qanash H; Li Y; Smith RH; Linask K; Young-Baird S; Hakami W; Keyvanfar K; Choy JS; Zou J; Larochelle A
    Cells; 2021 Mar; 10(4):. PubMed ID: 33810313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune thrombocytopenic purpura--from agony to agonist.
    Schwartz RS
    N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
    [No Abstract]   [Full Text] [Related]  

  • 14. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
    Serebruany VL; Eisert C; Sabaeva E; Makarov L
    Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
    Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
    Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
    Imbach P; Crowther M
    N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
    Cela I; Miller IJ; Katz RS; Rizman A; Shammo JM
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):806-9. PubMed ID: 21326158
    [No Abstract]   [Full Text] [Related]  

  • 18. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
    N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
    Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
    Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of thrombopoietic agents.
    Rhodes E; Stasi R
    Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.